Article
|
Open Access
Featured
-
-
Analysis
| Open AccessRefining the impact of genetic evidence on clinical success
Human genetic evidence increases the success rate of drugs from clinical development to approval but we are still far from reaching peak genetic insights to aid the discovery of targets for more effective drugs.
- Eric Vallabh Minikel
- , Jeffery L. Painter
- & Matthew R. Nelson
-
Article
| Open AccessConcurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
RMC-7977, a compound that exhibits potent inhibition of the active states of mutant and wild-type KRAS, NRAS and HRAS variants has a strong anti-tumour effect on RAS-addicted tumours and is well tolerated in preclinical models.
- Matthew Holderfield
- , Bianca J. Lee
- & Mallika Singh
-
Article |
TRBC1-targeting antibody–drug conjugates for the treatment of T cell cancers
Anti-TRBC1 antibody–drug conjugates may offer a more potent T cell cancer therapy by bypassing the fratricide that may be limiting the efficacy of anti-TRBC1 CAR T cells in the clinical trial for patients with T cell cancers.
- Tushar D. Nichakawade
- , Jiaxin Ge
- & Suman Paul
-
Article
| Open AccessTargeting myeloid chemotaxis to reverse prostate cancer therapy resistance
A translational study demonstrates the role of myeloid inflammatory cells in driving disease progression and treatment resistance in prostate cancer and shows that these cells can be targeted therapeutically.
- Christina Guo
- , Adam Sharp
- & Johann S. de Bono
-
Review Article |
From target discovery to clinical drug development with human genetics
This Review provides a perspective on the development of non-cancer therapies based on human genetics studies and suggests measures that can be taken to streamline the pipeline from initial genetic discovery to approved therapy.
- Katerina Trajanoska
- , Claude Bhérer
- & Vincent Mooser
-
Article
| Open AccessA framework for individualized splice-switching oligonucleotide therapy
Whole-genome sequencing analyses in a cohort of individuals with ataxia-telangiectasia are used to identify genetic variants that might be amenable to treatment with splice-switching antisense oligonucleotides (ASOs), and develop ASOs with therapeutic potential.
- Jinkuk Kim
- , Sijae Woo
- & Timothy W. Yu
-
Article
| Open AccessEngineered tRNAs suppress nonsense mutations in cells and in vivo
Suppressor tRNAs adapted to the amino acid that they carry enable readthrough of premature termination codons introduced by nonsense mutations and show potential for the treatment of genetic diseases such as cystic fibrosis.
- Suki Albers
- , Elizabeth C. Allen
- & Zoya Ignatova
-
Article
| Open AccessTeixobactin kills bacteria by a two-pronged attack on the cell envelope
Using a combination of methods, the mechanism of the antibiotic teixobactin is revealed.
- Rhythm Shukla
- , Francesca Lavore
- & Markus Weingarth
-
Article
| Open AccessStructural insights into inhibitor regulation of the DNA repair protein DNA-PKcs
Cryo-electron microscopy structures of DNA-dependent protein kinase catalytic subunit bound to ATPγS and four inhibitors (wortmannin, NU7441, AZD7648 and M3814) provide molecular details and insights useful for drug design.
- Shikang Liang
- , Sherine E. Thomas
- & Tom L. Blundell
-
Article
| Open AccessLong-acting capsid inhibitor protects macaques from repeat SHIV challenges
A single dose of a small-molecule HIV capsid inhibitor provides long-term protection from repeated simian–human immunodeficiency virus challenges in macaques and might serve as a novel strategy for HIV prevention in humans.
- Samuel J. Vidal
- , Elena Bekerman
- & Dan H. Barouch
-
Article |
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
In a phase-I/II trial in healthy adults, the BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells against SARS-CoV-2 epitopes that are conserved in a wide range of currently circulating variants.
- Ugur Sahin
- , Alexander Muik
- & Özlem Türeci
-
Article |
Structural basis of antifolate recognition and transport by PCFT
Cryo-electron microscopy structures of PCFT in a substrate-free state and bound to the antifolate drug pemetrexed provide insights into how this protein recognizes folates and mediates their transport into cells.
- Joanne L. Parker
- , Justin C. Deme
- & Simon Newstead
-
Article |
Structural basis for the action of the drug trametinib at KSR-bound MEK
Crystal structures of the MEK kinase bound to the scaffold protein KSR and various MEK inhibitors, including the anti-cancer drug trametinib, reveal the molecular and functional mechanisms behind MEK inhibition.
- Zaigham M. Khan
- , Alexander M. Real
- & Arvin C. Dar
-
Article |
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
In a dose-escalation study of the COVID-19 RNA vaccine BNT162b1 in 45 healthy adults, RBD-binding IgG concentrations and SARS-CoV-2 neutralizing titres in sera increased with dose level and after a second vaccine dose.
- Mark J. Mulligan
- , Kirsten E. Lyke
- & Kathrin U. Jansen
-
Article |
Clinical targeting of HIV capsid protein with a long-acting small molecule
The small molecule GS-6207, which disrupts the function of the HIV capsid protein, shows potential as a long-acting therapeutic agent for the treatment and prevention of HIV infection.
- John O. Link
- , Martin S. Rhee
- & Tomas Cihlar
-
Review Article |
Why and where an HIV cure is needed and how it might be achieved
Current barriers and limitations to HIV treatments are reviewed, and suggestions for future steps to achieve an effective curative intervention are discussed.
- Thumbi Ndung’u
- , Joseph M. McCune
- & Steven G. Deeks
-
Review Article |
A view on drug resistance in cancer
A review of drug resistance in cancer analyses each biological determinant of resistance separately and discusses existing and new therapeutic strategies to combat the problem as a whole.
- Neil Vasan
- , José Baselga
- & David M. Hyman
-
Article |
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Treatment of KRASG12C-mutant cancer cells with the KRAS(G12C) inhibitor AMG 510 leads to durable response in mice, and anti-tumour activity in patients suggests that AMG 510 could be effective in patients for whom treatments are currently lacking.
- Jude Canon
- , Karen Rex
- & J. Russell Lipford
-
Letter |
Small-molecule ion channels increase host defences in cystic fibrosis airway epithelia
Amphotericin B forms nonselective transmembrane ion channels, and restores host defences of cystic fibrosis airway epithelia independently of the regulatory function of cystic fibrosis transmembrane conductance.
- Katrina A. Muraglia
- , Rajeev S. Chorghade
- & Martin D. Burke
-
Letter |
Efficacy of MEK inhibition in patients with histiocytic neoplasms
A proof-of-concept clinical trial of patients with histiocytoses with MAPK-pathway mutations showed durable responses to treatment with the MEK1 and MEK2 inhibitor cobimetinib, which indicates that histiocytic neoplasms are dependent on MAPK signalling.
- Eli L. Diamond
- , Benjamin H. Durham
- & David M. Hyman
-
Letter |
Actively personalized vaccination trial for newly diagnosed glioblastoma
In a phase I trial, highly individualized peptide vaccines against unmutated tumour antigens and neoepitopes elicited sustained responses in CD8+ and CD4+ T cells, respectively, in patients with newly diagnosed glioblastoma.
- Norbert Hilf
- , Sabrina Kuttruff-Coqui
- & Wolfgang Wick
-
Article |
Cryo-EM structure of the active, Gs-protein complexed, human CGRP receptor
The structure of a complex containing calcitonin gene-related peptide, the human calcitonin gene-related peptide receptor and the Gs heterotrimer, determined using Volta phase-plate cryo-electron microscopy, provides structural insight into the regulation of G-protein-coupled receptors by receptor activity modifying protein 1.
- Yi-Lynn Liang
- , Maryam Khoshouei
- & Patrick M. Sexton
-
Letter |
Activity-dependent neuroprotective protein recruits HP1 and CHD4 to control lineage-specifying genes
ADNP interacts with the chromatin remodeller CHD4 and the heterochromatin protein HP1 to form a complex termed ChAHP that represses gene expression independently of the histone H3K9me3 modification.
- Veronika Ostapcuk
- , Fabio Mohn
- & Marc Bühler
-
Article |
HER kinase inhibition in patients with HER2- and HER3-mutant cancers
In a basket trial design, the efficacy of the pan-HER kinase inhibitor neratinib is tested in patients with 21 different tumour types, and responses are determined by mutation and tissue type, and are restricted to HER2-mutant cancers.
- David M. Hyman
- , Sarina A. Piha-Paul
- & David B. Solit
-
Article |
Visualization of chemical modifications in the human 80S ribosome structure
A high-resolution structure of the human ribosome determined by cryo-electron microscopy visualizes numerous RNA modifications that are concentrated at functional sites with an extended shell, and suggests the possibility of designing more specific ribosome-targeting drugs.
- S. Kundhavai Natchiar
- , Alexander G. Myasnikov
- & Bruno P. Klaholz
-
Letter |
CDK4/6 inhibition triggers anti-tumour immunity
Mouse models of breast carcinoma and other solid tumours show that selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors not only induce tumour cell cycle arrest but also promote anti-tumour immunity.
- Shom Goel
- , Molly J. DeCristo
- & Jean J. Zhao
-
Letter |
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
The authors report the first-in-human application of personalized neo-antigen RNA vaccines in patients with melanoma.
- Ugur Sahin
- , Evelyna Derhovanessian
- & Özlem Türeci
-
Letter |
Antisense oligonucleotide therapy for spinocerebellar ataxia type 2
Antisense oligonucleotides against ATXN2 improved motor neuron function and restored firing frequency in cerebellar Purkinje cells in mouse models of spinocerebellar ataxia type 2.
- Daniel R. Scoles
- , Pratap Meera
- & Stefan M. Pulst
-
Letter |
The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1
The selective allosteric ABL1 inhibitor ABL001 (asciminib) represents a new inhibitory mechanism for BCR–ABL1-driven malignancies, and its efficacy and evolving mechanisms of resistance do not overlap with those of other BCR–ABL1 kinase inhibitors.
- Andrew A. Wylie
- , Joseph Schoepfer
- & William R. Sellers
-
Article |
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
S63845 specifically inhibits MCL1 and induces tumour cell death in vitro and in vivo in diverse cancer-derived cell lines with an acceptable safety margin.
- András Kotschy
- , Zoltán Szlavik
- & Olivier Geneste
-
Article |
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Aducanumab, a human monoclonal antibody that selectively targets aggregated Aβ, reduces soluble and insoluble Aβ in the brain, an action accompanied by a dose-dependent slowing of clinical decline in treated patients.
- Jeff Sevigny
- , Ping Chiao
- & Alfred Sandrock
-
Letter |
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
SHP099, a selective inhibitor of signalling meditator SHP2 with drug-like properties, has an allosteric mechanism of action whereby it stabilizes SHP2 in an auto-inhibited conformation, and suppresses RAS–ERK signalling and proliferation in receptor-tyrosine-kinase-driven cancer cell lines and mouse tumour xenograft models.
- Ying-Nan P. Chen
- , Matthew J. LaMarche
- & Pascal D. Fortin
-
Letter |
Rocaglates convert DEAD-box protein eIF4A into a sequence-selective translational repressor
The cancer drug rocaglamide A cements the RNA helicase eIF4A on polypurine sequences and thereby prevents scanning of the 43S subunit along the messenger RNA, highlighting how a drug can act by stabilizing sequence-selective RNA–protein interactions.
- Shintaro Iwasaki
- , Stephen N. Floor
- & Nicholas T. Ingolia
-
Letter |
Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
The discovery is reported of a small molecule drug, GS-5734, which has antiviral activity against Ebola virus and other filoviruses, and is capable of providing post-exposure therapeutic protection against lethal disease in 100% of drug-treated nonhuman primates infected with Ebola virus; the drug targets viral RNA polymerase and can distribute to sanctuary sites (such as testes, eyes and brain), suggesting that it may be able to clear persistent virus infection.
- Travis K. Warren
- , Robert Jordan
- & Sina Bavari
-
Article |
Structural integration in hypoxia-inducible factors
This study describes the long-awaited crystal structures for hypoxia-inducible factor (HIF) heterodimers, including complexes bound to small molecules and DNA; the HIF–ARNT architecture is distinct from the bHLH-PAS-containing CLOCK–BMAL1 heterodimer, and HIF mutations linked to cancer can be mapped to important structural regions, with the structures providing future reference for small-molecule drug discovery efforts.
- Dalei Wu
- , Nalini Potluri
- & Fraydoon Rastinejad
-
Inside View |
Inside View: Pfizer
-
Letter |
Discovery and characterization of small molecules that target the GTPase Ral
Using a structure-based approach, small molecule inhibitors that selectively target the GTPase Ral are identified and characterized; these first-generation inhibitors will be valuable tools for elucidating the Ral signalling pathway and constitute a step towards developing Ral-specific agents for cancer therapy.
- Chao Yan
- , Degang Liu
- & Dan Theodorescu
-
-
Outlook |
Drug development: Illuminated targets
The development of effective antiepilepsy drugs is moving on from trial-and-error approaches to sophisticated molecular solutions.
- Megan Cully
-
-
Outlook |
Therapy: This time it's personal
Tailoring cancer treatment to individual and evolving tumours is the way of the future, but scientists are still hashing out the details.
- Lauren Gravitz
-
Outlook |
Clinical trials: More trials, fewer tribulations
Clinical studies that group patients according to their molecular profile can make for better and faster drug approval decisions.
- Michael Eisenstein
-
Outlook |
Drug development: Time for teamwork
In the face of more drug-resistant bugs and fewer new drugs, partnerships promise a resurgence of antibiotics.
- Mike May
-
Outlook |
Drug development: The modelling challenge
Researchers have made good progress with animal tests for cognition. The next step is to devise a rodent model for drug development.
- Alla Katsnelson
-
Outlook |
Therapeutics: Negative feedback
Schizophrenia debilitates not just by psychosis but by depriving people of the ability to feel pleasure.
- Elie Dolgin
-
Article |
Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy
A chemoproteomic screen is used here to identify MTH1 as the target of SCH51344, an experimental RAS-dependent cancer drug; a further search for inhibitors revealed (S)-crizotinib as a potent MTH1 antagonist, which suppresses tumour growth in animal models of colon cancer, and could be part of a new class of anticancer drugs.
- Kilian V. M. Huber
- , Eidarus Salah
- & Giulio Superti-Furga
-
Outlook |
Drug development: Releasing the brakes
Tumours can put a brake on the immune system, but new therapies work by removing these brakes. Now, researchers have to figure out how to use them most effectively.
- Karen Weintraub
-
Outlook |
Drug development: Chemical brace
Drugs to protect vulnerable neurons and encourage neural circuits to reform could one day improve the outlook for patients with acute spinal cord trauma.
- Megan Cully
-
Outlook |
Drug Discovery: Structure-led design
Knowing the structures of G-protein-coupled receptors, says Lindau keynote speaker Brian Kobilka, should help with drug development. But how is this progressing?
- Monica Hoyos Flight